Logo Image
NEWS
Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted Pulse
CONFERENCES
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
MEDIA
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPractice PlaybookShortsVideo Series
PUBLICATIONS
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
More
CASE-BASED ROUNDTABLE
PARTNERS
RESOURCES
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
  • NEWS
  • CONFERENCES
  • MEDIA
  • PUBLICATIONS
  • CASE-BASED ROUNDTABLE
  • PARTNERS
  • RESOURCES
  • SUBSCRIBE
  • BRAIN CANCER
  • BREAST CANCER
    • HER2 Breast Cancer
  • COMMUNITY ONCOLOGY PRACTICE
  • GENITOURINARY CANCERS
    • Bladder Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
  • GENOMIC TESTING
    • Liquid Biopsies
  • GI CANCERS
    • Pancreatic Cancer
    • Colorectal Cancer
    • Gastric Cancer
    • GIST
    • HCC
  • GYNECOLOGIC CANCERS
    • Cervical Cancer
    • Endometrial Cancer
    • Ovarian Cancer
  • HEAD & NECK CANCERS
  • HEMATOLOGY
    • Bone Marrow & Stem Cell Transplant
  • IMMUNOTHERAPY
    • CAR T-Cell Therapy
  • LEUKEMIAS
    • AML
    • Chronic Lymphocytic Leukemia
    • Chronic Myeloid Leukemia
  • LUNG CANCER
    • MET-Targeted Therapy
    • Small Cell Lung Cancer
    • Biomarker-Driven Lung Cancer
    • EGFR+ Lung Cancer
  • LYMPHOMAS
    • DLBCL
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
  • MPNs
  • MULTIPLE MYELOMA
  • NTRK GENE FUSIONS
  • ONCOLOGY POLICY
  • SARCOMA
  • SKIN CANCERS
    • Melanoma
  • THYROID CANCERS
Spotlight -
Community Oncology Practice|
Oncology Policy|
Myeloma|
CLL|
Genomic Testing|
GU Cancers
Advertisement

Jonathon B. Cohen, MD, MS

Advertisement

Articles by Jonathon B. Cohen, MD, MS

Next Steps in Relapsed/Refractory Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

BTK Inhibitors in MCL: Long-Term Safety & Efficacy Data

ByJonathon B. Cohen, MD, MS
May 18th 2020

BTK Inhibitor Toxicities in Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

Administration of BTK Inhibitors for Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

Relapsed Mantle Cell Lymphoma Treatment Landscape

ByJonathon B. Cohen, MD, MS
May 18th 2020

Initiating Therapy for Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

Diagnosing MCL and Making Informed Treatment Decisions

ByJonathon B. Cohen, MD, MS
May 18th 2020

Case Assessment: 68-Year-Old Patient With MCL

ByJonathon B. Cohen, MD, MS
May 18th 2020

A 68-Year-Old Man With Mantle Cell Lymphoma

ByJonathon B. Cohen, MD, MS
May 18th 2020

Recommendations for treating a 68-year-old male with mantle cell lymphoma with a BTK inhibitor once he has relapsed on prior therapy.

Advertisement

Latest Updated Articles

  • Case Assessment: 68-Year-Old Patient With MCL
    Case Assessment: 68-Year-Old Patient With MCL

    May 18th 2020

  • Relapsed Mantle Cell Lymphoma Treatment Landscape
    Relapsed Mantle Cell Lymphoma Treatment Landscape

    May 18th 2020

  • Diagnosing MCL and Making Informed Treatment Decisions
    Diagnosing MCL and Making Informed Treatment Decisions

    May 18th 2020

  • Administration of BTK Inhibitors for Mantle Cell Lymphoma
    Administration of BTK Inhibitors for Mantle Cell Lymphoma

    May 18th 2020

  • Initiating Therapy for Mantle Cell Lymphoma
    Initiating Therapy for Mantle Cell Lymphoma

    May 18th 2020

  • BTK Inhibitor Toxicities in Mantle Cell Lymphoma
    BTK Inhibitor Toxicities in Mantle Cell Lymphoma

    May 18th 2020



Advertisement
Advertisement

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

1

ASCO 2026 GU Cancer Highlights: Beyond the LBAs

2

FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer

3

Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma

4

ASCO 2026 GI Cancer Highlights: Beyond the LBAs

5

FDA Grants Fast Track Designation to VS-7375 for KRAS G12D–Mutated NSCLC

  • About Us
  • Advertise
  • Contact Us
  • CureToday.com
  • CancerNetwork.com
  • OncLive.com
  • OncNursingNews.com
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
  • Editorial Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us